๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Diffuse Large B Cell Lymphoma
Clinical trial register · Germany

Diffuse Large B Cell Lymphoma Trials in Germany, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 5051 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:51 UTC
5051
Studies in scope
all four open statuses
2882
Recruiting now
open to new participants
988
Lead sponsors
across recruiting studies
Top sites
Berlin 7 Cologne 4 Dresden 3 Halle 3 Homburg 2
Narrow the registerReset
Recruitment status
Phase
Site location
Berlin7 Cologne4 Dresden3 Halle3 Homburg2
All 33 locations
Target enrolment
to

Diffuse Large B Cell Lymphoma trials in Germany

12 of 5051 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Recruiting
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
NCT06395103B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma
Merck Sharp & Dohme LLC
Phase 1/2
90
Tรผbingen, Cologne, Mรผnster, Berlin
2024-08-16
Recruiting
Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma
NCT05820841Large B-cell Lymphoma, Diffuse Large B Cell Lymphoma
Universitรคt des Saarlandes
Phase 3
330
Homburg, Aschaffenburg, Berlin, Dresden, Giessen, Greifswald, Halle, Karlsruhe
2023-06-07
Recruiting
A Non-interventional, International, Multicentre Clinical Research Study to Build the Largest Collection of Multimodal Data (Including Clinical Data, Imaging Data and Omics Data) in Oncology
NCT06625203Diffuse Large B Cell Lymphoma, Solid Tumor Cancer
OWKIN
Observational
7,000
Berlin, Erlangen
2023-05-08
Active, closed
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
NCT05618028Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, B Cell Malignancies, Non-Hodgkin's Lymphoma
AbbVie
Phase 1
78
Berlin
2023-04-04
Recruiting
Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
NCT04844866Diffuse Large B-cell Lymphoma
Miltenyi Biomedicine GmbH
Phase 2
213
Augsburg, Bochum, Cologne, Erlangen, Essen, Hamburg, Heidelberg, Leipzig
2021-08-18
Active, closed
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
NCT04824092Diffuse Large B-cell Lymphoma
Incyte Corporation
Phase 3
899
Aachen, Augsburg, Berlin, Bonn, Chemnitz, Cottbus, Gรถttingen, Halle
2021-05-11
Active, closed
A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
NCT04628494Diffuse Large B-cell Lymphoma
Genmab
Phase 3
483
Cologne, Essen, Kiel, Wรผrzburg
2021-01-13
Active, closed
A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)
NCT04529772Diffuse Large B-Cell Lymphoma
Acerta Pharma BV
Phase 3
611
Bamberg, Berlin, Dresden, Homburg, Neumรผnster
2020-10-08
Active, closed
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
NCT03960840Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia
Novartis Pharmaceuticals
Phase 1/2
217
Frankfurt am Main, Leipzig
2019-06-26
Recruiting
Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR
NCT03676504Acute Lymphoblastic Leukemia, Adult, Acute Lymphoblastic Leukemia, Pediatric, Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma
University Hospital Heidelberg
Phase 1/2
68
Heidelberg
2018-09-07
Active, closed
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
NCT02227251Diffuse Large B-cell Lymphoma
Karyopharm Therapeutics Inc
Phase 2
244
Aachen, Bad Saarow, Berlin, Bremen, Cologne, Dresden, Halle, Hanover
2014-11
Rows per page Showing 1–12 of 12
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 28 September 2026. https://priyalifescience.com/clinical-trials-germany/condition/diffuse-large-b-cell-lymphoma

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,051 studies in total at the last sync on 26 Sep 2026, 19:51 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 12 of those studies listing the condition Diffuse Large B Cell Lymphoma.

How many Diffuse Large B Cell Lymphoma trials are recruiting in Germany?

5 of the 12 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:51 UTC sync. A further 0 have not yet opened recruitment, 7 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Diffuse Large B Cell Lymphoma), 12 studies
PhaseStudiesRecruitingShare
Phase 35141.7%
Phase 1/23225%
Phase 22116.7%
Observational118.3%
Phase 1108.3%

Most active sponsors

Lead sponsors with the most studies (Diffuse Large B Cell Lymphoma)
Lead sponsorStudiesRecruiting
AbbVie10
Acerta Pharma BV10
Genmab10
Hoffmann-La Roche10
Incyte Corporation10
Karyopharm Therapeutics Inc10
Merck Sharp & Dohme LLC11
Miltenyi Biomedicine GmbH11
Novartis Pharmaceuticals10
OWKIN11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.